NovaBay Pharmaceuticals Inc. (NBY) and Sutro Biopharma Inc. (NASDAQ:STRO) Comparison side by side

Both NovaBay Pharmaceuticals Inc. (NYSEAMERICAN:NBY) and Sutro Biopharma Inc. (NASDAQ:STRO) are Biotechnology companies, competing one another. We will compare their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NovaBay Pharmaceuticals Inc. 15.20M 1.60 4.48M 0.55 2.53
Sutro Biopharma Inc. 23.37M 11.19 49.17M -2.21 0.00

Table 1 demonstrates NovaBay Pharmaceuticals Inc. and Sutro Biopharma Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 represents NovaBay Pharmaceuticals Inc. (NYSEAMERICAN:NBY) and Sutro Biopharma Inc. (NASDAQ:STRO)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
NovaBay Pharmaceuticals Inc. -29.47% -71.9% -39%
Sutro Biopharma Inc. -210.40% 0% 0%


NovaBay Pharmaceuticals Inc. has a Current Ratio of 2.8 and a Quick Ratio of 2.7. Competitively, Sutro Biopharma Inc.’s Current Ratio is 3.5 and has 3.5 Quick Ratio. Sutro Biopharma Inc.’s better ability to pay short and long-term obligations than NovaBay Pharmaceuticals Inc.

Institutional & Insider Ownership

NovaBay Pharmaceuticals Inc. and Sutro Biopharma Inc. has shares owned by institutional investors as follows: 1% and 75.3%. Insiders owned roughly 25.78% of NovaBay Pharmaceuticals Inc.’s shares. Comparatively, Sutro Biopharma Inc. has 8.5% of it’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
NovaBay Pharmaceuticals Inc. -6.67% -25.69% 12.91% -17.65% -59.94% 81.18%
Sutro Biopharma Inc. -9.77% -14.46% -12.05% 0% 0% 0.33%

For the past year NovaBay Pharmaceuticals Inc.’s stock price has bigger growth than Sutro Biopharma Inc.


NovaBay Pharmaceuticals Inc. beats Sutro Biopharma Inc. on 6 of the 11 factors.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.